0000950170-24-014534.txt : 20240213 0000950170-24-014534.hdr.sgml : 20240213 20240213160521 ACCESSION NUMBER: 0000950170-24-014534 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20240208 ITEM INFORMATION: Material Modifications to Rights of Security Holders ITEM INFORMATION: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240213 DATE AS OF CHANGE: 20240213 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ASSEMBLY BIOSCIENCES, INC. CENTRAL INDEX KEY: 0001426800 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35005 FILM NUMBER: 24625660 BUSINESS ADDRESS: STREET 1: TWO TOWER PLACE STREET 2: 7TH FLOOR CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: (833) 409-4583 MAIL ADDRESS: STREET 1: TWO TOWER PLACE STREET 2: 7TH FLOOR CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 FORMER COMPANY: FORMER CONFORMED NAME: VENTRUS BIOSCIENCES INC DATE OF NAME CHANGE: 20080211 8-K 1 asmb-20240208.htm 8-K 8-K
false0001426800--12-3100014268002024-02-082024-02-08

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 8, 2024

Assembly Biosciences, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware

001-35005

20-8729264

(State or Other Jurisdiction

of Incorporation)

(Commission File Number)

(IRS Employer

Identification No.)

 

 

 

Two Tower Place, 7th Floor,

South San Francisco, California

94080

(Address of Principal Executive Offices)

(Zip Code)

Registrant’s Telephone Number, Including Area Code: (833) 509-4583

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading

Symbol(s)

 

Name of each exchange on which registered

Common Stock, par value $0.001

 

ASMB

 

The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

Item 3.03 Material Modification to Rights of Security Holders.

The information contained in Item 5.03 below is incorporated by reference into this Item 3.03.

Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

On February 9, 2024, Assembly Biosciences, Inc. (the "Company"), filed an amendment (the "Amendment") to its Sixth Amended and Restated Certificate of Incorporation (the "Charter") with the Secretary of State of the State of Delaware to effect a 1-for-12 reverse stock split (the "Reverse Stock Split") of the Company's common stock, par value $0.001 (the "Common Stock"). The Amendment became effective on February 9, 2024. As previously disclosed, at its special meeting of stockholders held on January 31, 2024 (the "Special Meeting"), the Company's stockholders approved a proposal to authorize the Company's Board of Directors (the "Board") to amend the Charter to effect a reverse stock split at a ratio between 1-for-7 and 1-for-17 (or any number in between), as determined by the Board in its discretion. On January 31, 2024, the Board approved the Reverse Stock Split at a ratio of 1-for-12.

On February 12, 2024, the Common Stock began trading on a split-adjusted basis under a new CUSIP number, 045396207.

The Reverse Stock Split will affect all stockholders uniformly and will not alter any stockholder's percentage interest in the Company's equity, except to the extent that the Reverse Stock Split would result in a stockholder owning a fractional share of Common Stock. No fractional shares will be issued in connection with the Reverse Stock Split. Stockholders who would otherwise be entitled to a fractional share of Common Stock are instead entitled to a cash payment equal to the fraction multiplied by the closing price of the Common Stock, as reported by Nasdaq, on the last trading day prior to the effective date of the Reverse Stock Split. The Reverse Stock Split will reduce the number of shares outstanding from approximately 65.8 million shares to approximately 5.5 million, subject to adjustment for fractional shares.

In addition, proportionate adjustments will be made to (1) the per share exercise price and number of shares issuable upon the exercise of all outstanding stock options to purchase shares of Common Stock, (2) the number of shares issuable upon the vesting of all outstanding restricted stock units and (3) the number of shares of Common Stock reserved for issuance pursuant to the Company's equity compensation plans.

The foregoing description of the Amendment does not purport to be complete and is qualified in its entirety by the full text of the Amendment, a copy of which is filed as Exhibit 3.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 8.01 Other Events.

On February 8, 2024, the Company issued a press release announcing the effective date of the Reverse Stock Split. A copy of the press release is filed as Exhibit 99.1 and is incorporated by reference into this Item 8.01.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

 

Exhibit

Number

Description

3.1

Certificate of Amendment to Sixth Amended and Restated Certificate of Incorporation, dated February 9, 2024.

99.1

Press Release dated February 8, 2024.

 104

Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

1

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

Assembly Biosciences, Inc.

Date: February 13, 2024

By:

/s/ John O. Gunderson

John O. Gunderson

VP, General Counsel and Corporate Secretary

 

2

 EX-3.1 2 asmb-ex3_1.htm EX-3.1 EX-3.1

Exhibit 3.1

CERTIFICATE OF AMENDMENT

OF

SIXTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF

ASSEMBLY BIOSCIENCES, INC.

ASSEMBLY BIOSCIENCES, INC., a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the “Corporation”), does hereby certify as follows:

FIRST: The name of the Corporation is Assembly Biosciences, Inc.

SECOND: The Corporation’s original Certificate of Incorporation was filed with the Secretary of State of the State of Delaware on October 7, 2005, under the name South Island Biosciences, Inc., an Amended and Restated Certificate of Incorporation was filed with the Secretary of State of the State of Delaware on October 24, 2005, a second Amended and Restated Certificate of Incorporation, which included a provision to change the Corporation’s name to Ventrus Biosciences, Inc., was filed with the Secretary of State of the State of Delaware on April 5, 2007 (the “Second Amended and Restated Certificate of Incorporation”), a third Amended and Restated Certificate of Incorporation was filed with the Secretary of State of the State of Delaware on November 10, 2010 (the “Third Amended and Restated Certificate of Incorporation”) and a Certificate of Amendment of the Third Amended and Restated Certificate of Incorporation was filed with the Secretary of State of the State of Delaware on July 10, 2014, which included a provision to change the Corporation’s name to Assembly Biosciences, Inc., a Fourth Amended and Restated Certificate of Incorporation was filed with the Secretary of State of the State of Delaware on May 31, 2018, a Fifth Amended and Restated Certificate of Incorporation was filed with the Secretary of State of the State of Delaware on June 12, 2020, and a Sixth Amended and Restated Certificate of Incorporation was filed with the Secretary of State of the State of Delaware on May 25, 2022.

THIRD: That the Board of Directors of the Corporation adopted resolutions setting forth a proposed amendment of the Corporation’s Sixth Amended and Restated Certificate of Incorporation, declaring such amendment to be advisable and in the best interests of the Corporation and its stockholders and authorizing the appropriate officers of the Corporation to solicit the consent of the stockholders therefor, which resolution setting forth the proposed amendment is as follows:

RESOLVED, that Article IV of the Sixth Amended and Restated Certificate of Incorporation be amended to insert the following text at the end of the third paragraph:

“Effective as of 5:00 p.m., Eastern time, on the date this Certificate of Amendment to the Sixth Amended and Restated Certificate of Incorporation is filed with the Secretary of State of the State of Delaware, each 12 shares of the Corporation’s Common Stock, par value $0.001 per share, issued and outstanding shall, automatically and without any action on the part of the respective holders thereof, be combined and converted into one (1) share of Common Stock, par value $0.001 per share, of the Corporation. No fractional shares shall be issued and, in lieu thereof, any holder of less than one (1) share of Common Stock shall be entitled to receive cash for such holder’s fractional share based upon the closing sales price of the Corporation’s Common Stock as reported on the Nasdaq Global Select Market, as of the date this Certificate of Amendment is filed with the Secretary of State of the State of Delaware.”

FOURTH: This Certificate of Amendment of the Amended and Restated Certificate of Incorporation has been duly adopted by the stockholders of the Corporation in accordance with the provisions of Section 242 of the Delaware General Corporation Law.

 

 

IN WITNESS WHEREOF, the Corporation has caused this Certificate of Amendment of the Sixth Amended and Restated Certificate of Incorporation to be signed by its Chief Executive Officer and President this 9th day of February, 2024.

 

/s/ Jason A. Okazaki

Jason A. Okazaki

Chief Executive Officer and President

 

 

 EX-99.1 3 asmb-ex99_1.htm EX-99.1 EX-99.1

Exhibit 99.1

Assembly Biosciences Announces Effective Date of Reverse Stock Split

– Assembly Bio common stock expected to begin trading on a split-adjusted basis on February 12, 2024 –

 

SOUTH SAN FRANCISCO, Calif., Feb. 8, 2024 -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative antiviral therapeutics targeting serious viral diseases, today announced that it expects a 1-for-12 reverse stock split of its outstanding shares of common stock will be effective as of February 9, 2024. The company anticipates that its common stock will begin trading on a split-adjusted basis on The Nasdaq Global Select Market under the same symbol (ASMB) when the market opens on February 12, 2024, with the new CUSIP number 045396207.

As of the effective time of the reverse stock split, every 12 issued and outstanding shares of the company’s common stock will be automatically reclassified into one issued and outstanding share of the company’s common stock. This will reduce the number of shares outstanding from approximately 65.8 million shares to approximately 5.5 million, subject to adjustment for fractional shares. The reverse stock split will not affect the number of authorized shares of common stock or the par value of the common stock.

Equiniti Trust Company, LLC, is acting as the exchange agent for the reverse stock split. Registered stockholders holding pre-split shares of the company's common stock are not required to take any action to receive post-split shares. Stockholders owning shares via a broker, bank, trust or other nominee will have their positions automatically adjusted to reflect the reverse stock split, subject to such broker's particular processes, and will not be required to take any action in connection with the reverse stock split. Stockholders holding shares of the company's common stock in certificate form will receive a transmittal letter from Equiniti with instructions as soon as practicable after the effective date.

The reverse stock split is primarily intended to bring the company into compliance with the minimum bid price requirement for maintaining its listing on The Nasdaq Global Select Market. The reverse stock split was approved by the company’s stockholders at its special meeting of stockholders held on January 31, 2024. After this meeting, Assembly Bio’s board of directors approved the reverse stock split at a ratio of 1-for-12. Additional information about the reverse stock split can be found in the company’s definitive proxy statement filed with the Securities and Exchange Commission on December 21, 2023, which is available free of charge at the SEC’s website, www.sec.gov, and on the company’s website at www.assemblybio.com.

About Assembly Biosciences

Assembly Biosciences is a biotechnology company dedicated to the development of innovative small-molecule antiviral therapeutics designed to change the path of serious viral diseases and improve the lives of patients worldwide. Led by an accomplished team of leaders in virologic drug development, Assembly Bio is committed to improving outcomes for patients struggling with the serious, chronic impacts of herpesvirus, hepatitis B virus (HBV) and hepatitis delta virus (HDV) infections. For more information, visit assemblybio.com. 

 

 

Forward-Looking Statements

The information in this press release contains forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to materially differ. These risks and uncertainties include: statements regarding the timing of the reverse stock split; Assembly Bio’s ability to regain compliance with the Nasdaq minimum bid price requirement; Assembly Bio’s ability to realize the potential benefits of its collaboration with Gilead Sciences, Inc. (Gilead), including all financial aspects of the collaboration and equity investments; Assembly Bio’s ability to initiate and complete clinical studies involving its therapeutic product candidates, including studies contemplated by Assembly Bio’s collaboration with Gilead, in the currently anticipated timeframes or at all; the occurrence of any event, change or other circumstance that could give rise to the termination of Assembly Bio’s collaboration with Gilead; safety and efficacy data from clinical or nonclinical studies may not warrant further development of Assembly Bio’s product candidates; clinical and nonclinical data presented at conferences may not differentiate Assembly Bio’s product candidates from other companies’ candidates; results of nonclinical studies may not be representative of disease behavior in a clinical setting and may not be predictive of the outcomes of clinical studies; and other risks identified from time to time in Assembly Bio’s reports filed with the U.S. Securities and Exchange Commission (the SEC). You are urged to consider statements that include the words may, will, would, could, should, might, believes, hopes, estimates, projects, potential, expects, plans, anticipates, intends, continues, forecast, designed, goal or the negative of those words or other comparable words to be uncertain and forward-looking. Assembly Bio intends such forward-looking statements to be covered by the safe harbor provisions contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. More information about Assembly Bio’s risks and uncertainties are more fully detailed under the heading “Risk Factors” in Assembly Bio’s filings with the SEC, including its most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. Except as required by law, Assembly Bio assumes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

 

Contacts

Investor and Corporate: 

Shannon Ryan 

SVP, Investor Relations, Corporate Affairs and Alliance Management 

(415) 738-2992 

investor_relations@assemblybio.com

 

Media: 

Sam Brown Inc.

Hannah Hurdle

(805) 338-4752

ASMBMedia@sambrown.com 

EX-101.SCH 4 asmb-20240208.xsd XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT 100000 - Document - Document And Entity Information link:presentationLink link:calculationLink link:definitionLink Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Entity Address, State or Province Entity Address, State or Province Trading Symbol Trading Symbol Soliciting Material Soliciting Material Entity Address, City or Town Entity Address, City or Town Written Communications Written Communications Entity Central Index Key Entity Central Index Key Entity Tax Identification Number Entity Tax Identification Number Entity Registrant Name Entity Registrant Name Current Fiscal Year End Date Document Period End Date Document Period End Date Entity Address, Postal Zip Code Entity Address, Postal Zip Code Entity Incorporation, State or Country Code Entity Incorporation State Country Code Local Phone Number Local Phone Number City Area Code City Area Code Pre-commencement Tender Offer Pre-commencement Tender Offer Cover [Abstract] Cover Security Exchange Name Securtiy Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company Amendment Flag Amendment Flag Securities Act File Number Entity File Number Entity Address, Address Line Two Entity Address, Address Line One Entity Address, Address Line One Title of 12(b) Security Security 12b Title Document Type Document Type XML 5 R1.htm IDEA: XBRL DOCUMENT v3.24.0.1
Document And Entity Information
Feb. 08, 2024
Cover [Abstract]  
Entity Registrant Name Assembly Biosciences, Inc.
Document Type 8-K
Amendment Flag false
Entity Central Index Key 0001426800
Document Period End Date Feb. 08, 2024
Entity Emerging Growth Company false
Entity File Number 001-35005
Entity Incorporation State Country Code DE
Entity Tax Identification Number 20-8729264
Entity Address, Address Line One Two Tower Place
Entity Address, Address Line Two 7th Floor
Entity Address, City or Town South San Francisco
Entity Address, State or Province CA
Entity Address, Postal Zip Code 94080
City Area Code (833)
Local Phone Number 509-4583
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Security 12b Title Common Stock, par value $0.001
Trading Symbol ASMB
Securtiy Exchange Name NASDAQ
Current Fiscal Year End Date --12-31
EXCEL 7 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.0.1 html 1 24 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document And Entity Information Sheet http://www.assemblybio.com/20240208/taxonomy/role/Role_DocumentDocumentAndEntityInformation Document And Entity Information Cover 1 false false All Reports Book All Reports asmb-20240208.htm asmb-20240208.xsd http://xbrl.sec.gov/dei/2023 false false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "asmb-20240208.htm": { "nsprefix": "asmb", "nsuri": "http://www.assemblybio.com/20240208", "dts": { "inline": { "local": [ "asmb-20240208.htm" ] }, "schema": { "local": [ "asmb-20240208.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] } }, "keyStandard": 24, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 3, "http://xbrl.sec.gov/dei/2023": 3 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 25, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 24 }, "report": { "R1": { "role": "http://www.assemblybio.com/20240208/taxonomy/role/Role_DocumentDocumentAndEntityInformation", "longName": "100000 - Document - Document And Entity Information", "shortName": "Document And Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "C_58930f00-782f-4cf2-bfe3-93eb8c909e7d", "name": "dei:EntityRegistrantName", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "asmb-20240208.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_58930f00-782f-4cf2-bfe3-93eb8c909e7d", "name": "dei:EntityRegistrantName", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "asmb-20240208.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.assemblybio.com/20240208/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "terseLabel": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.assemblybio.com/20240208/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "terseLabel": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "terseLabel": "Cover", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://www.assemblybio.com/20240208/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.assemblybio.com/20240208/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "terseLabel": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.assemblybio.com/20240208/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "terseLabel": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.assemblybio.com/20240208/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://www.assemblybio.com/20240208/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.assemblybio.com/20240208/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.assemblybio.com/20240208/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.assemblybio.com/20240208/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.assemblybio.com/20240208/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.assemblybio.com/20240208/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.assemblybio.com/20240208/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Securities Act File Number", "terseLabel": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.assemblybio.com/20240208/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation State Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.assemblybio.com/20240208/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.assemblybio.com/20240208/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.assemblybio.com/20240208/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "terseLabel": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://www.assemblybio.com/20240208/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://www.assemblybio.com/20240208/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.assemblybio.com/20240208/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "terseLabel": "Security 12b Title", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.assemblybio.com/20240208/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "terseLabel": "Securtiy Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://www.assemblybio.com/20240208/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "terseLabel": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.assemblybio.com/20240208/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "terseLabel": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://www.assemblybio.com/20240208/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "terseLabel": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 14 0000950170-24-014534-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950170-24-014534-xbrl.zip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asmb-20240208_htm.xml IDEA: XBRL DOCUMENT 0001426800 2024-02-08 2024-02-08 false 0001426800 --12-31 8-K 2024-02-08 Assembly Biosciences, Inc. DE 001-35005 20-8729264 Two Tower Place 7th Floor South San Francisco CA 94080 (833) 509-4583 false false false false Common Stock, par value $0.001 ASMB NASDAQ false